Advances in Hematopoietic Stem Cell Transplantation in Childhood and Adolescent Lymphomas

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 1 SUPPL., 2013, Pages

  Cairo, Mitchell S ^a   Woessmann, Willi ^b   Pagel, John ^c  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ARABINOSIDE; BRENTUXIMAB VEDOTIN; BUSULFAN; CARMUSTINE; CRIZOTINIB; CYCLOPHOSPHAMIDE; CYTOSINE; ETOPOSIDE; FLUDARABINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN Y 90; IODINE 131; NANOPARTICLE; TETRAXETAN; UNCLASSIFIED DRUG; VINBLASTINE; YTTRIUM 90;

ADOLESCENT DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHILDHOOD CANCER; CLINICAL TRIAL (TOPIC); DONOR LYMPHOCYTE INFUSION; DRUG EFFICACY; DRUG SAFETY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; MYELOABLATIVE CONDITIONING; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; RISK FACTOR; SALVAGE THERAPY; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HISTIOCYTES; HODGKIN DISEASE; HUMANS; LYMPHOCYTES; MALE; REED-STERNBERG CELLS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS;

EID: 84871871767     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.10.003     Document Type: Article

References (32)

1. Hochberg J., Waxman I.M., Kelly K.M., et al. Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: State of the science. Br J Haematol 2009, 144:24-40.
2. Bradley M.B., Cairo M.S. Stem cell transplantation for pediatric lymphoma: Past, present and future. Bone Marrow Transplant 2008, 41:149-158.
3. Johnston L.J., Horning S.J. Autologous hematopoietic cell transplantation in Hodgkin's disease. Biol Blood Marrow Transplant 2000, 6:289-300.
4. Harris R.E., Termuhlen A.M., Smith L.M., et al. Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: Results of Children's Oncology Group study A5962. Biol Blood Marrow Transplant 2011, 17:249-258.
5. Jones R.J., Ambinder R.F., Piantadosi S., et al. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991, 77:649-653.
6. Carella A.M., Cavaliere M., Lerma E., et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 2000, 18:3918-3924.
7. Peggs K.S., Hunter A., Chopra R., et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005, 365:1934-1941.
8. Sureda A., Robinson S., Canals C., et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: An analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008, 26:455-462.
9. Peggs K.S., Kayani I., Edwards N., et al. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. J Clin Oncol 2011, 29:971-978.
10. Claviez A., Canals C., Dierickx D., et al. Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: An analysis of the European Group for Blood and Marrow Transplantation. Blood 2009, 114:2060-2067.
11. Cairo M.S., Geyer M.B., Harrison L., et al. Myeloablative (MAC) autologous stem cell transplantation (AutoSCT) followed by reduced Intensity (RIC) allogeneic stem cell transplantation (AlloSCT) in children, adolescents and young adults (CAYA) with poor risk Hodgkin's lymphoma (HL): Induction of long term GVHL effect. Biol Blood Marrow Transplant 2010, 16:S181.
12. Brugieres L., Quartier P., Le Deley M.C., et al. Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children-a report from the French Society of Pediatric Oncology. Ann Oncol 2000, 11:53-58.
13. Woessmann W., Zimmermann M., Lenhard M., et al. Relapsed or refractory anaplastic large-cell lymphoma in children and adolescents after Berlin-Frankfurt-Muenster (BFM)-type first-line therapy: A BFM-group study. J Clin Oncol 2011, 29:3065-3071.
14. Mori T., Takimoto T., Katano N., et al. Recurrent childhood anaplastic large cell lymphoma: A retrospective analysis of registered cases in Japan. Br J Haematol 2006, 132:594-597.
15. Williams D.M., Hobson R., Imeson J., et al. Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children's Cancer Study Group chemotherapy regimens. Br J Haematol 2002, 117:812-820.
16. Woessmann W., Peters C., Lenhard M., et al. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents-a Berlin-Frankfurt-Munster group report. Br J Haematol 2006, 133:176-182.
17. Mori T., Kiyokawa N., Shimada H., et al. Anaplastic large cell lymphoma in Japanese children: retrospective analysis of 34 patients diagnosed at the National Research Institute for Child Health and Development. Br J Haematol 2003, 121:94-96.
18. Reiter A., Schrappe M., Tiemann M., et al. Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: A prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies. J Clin Oncol 1994, 12:899-908.
19. Seidemann K., Tiemann M., Schrappe M., et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: A report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 2001, 97:3699-3706.
20. Brugieres L., Pacquement H., Le Deley M.C., et al. Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: A report from the French Society of Pediatric Oncology. J Clin Oncol 2009, 27:5056-5061.
21. Gross T.G., Hale G.A., He W., et al. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant 2010, 16:223-230.
22. Cesaro S., Pillon M., Visintin G., et al. Unrelated bone marrow transplantation for high-risk anaplastic large cell lymphoma in pediatric patients: A single center case series. Eur J Haematol 2005, 75:22-26.
23. Gambacorti-Passerini C., Messa C., Pogliani E.M. Crizotinib in anaplastic large-cell lymphoma. N Engl J Med 2011, 364:775-776.
24. Pro B., Advani R., Brice P., et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study. J Clin Oncol 2012, 30:2190-2196.
25. Shimoni A., Avivi I., Rowe J.M., et al. A multi-center prospective randomized study comparing ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherpay (Z-BEAM) vs. BEAM alone as the conditioning regimen prior to autologous stem cell transplantation in patients with aggressive lymphoma; Possible advantage for Z-BEAM in low-risk patients. Blood 2010, 116(suppl 21). Abstract 686.
26. Liu S.Y., Eary J.F., Petersdorf S.H., et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 1998, 16:3270-3278.
27. Bierman P.J., Vose J.M., Leichner P.K., et al. Yttrium 90-labeled antiferritin followed by high-dose chemotherapy and autologous bone marrow transplantation for poor-prognosis Hodgkin's disease. J Clin Oncol 1993, 11:698-703.
28. Gopal A.K., Guthrie K.A., Rajendran J., et al. (9)(0)Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma. Blood 2011, 118:1132-1139.
29. Gopal A.K., Press O.W., Wilbur S.M., et al. Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood 2008, 112:830-835.
30. Moghimi S.M., Hunter A.C., Murray J.C. Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol Rev 2001, 53:283-318.
31. Zhang H., Burnum K.E., Luna M.L., et al. Quantitative proteomics analysis of adsorbed plasma proteins classifies nanoparticles with different surface properties and size. Proteomics 2011, 11:4569-4577.
32. Walter R.B., Press O.W., Pagel J.M. Pretargeted radioimmunotherapy for hematologic and other malignancies. Cancer Biother Radiopharm 2010, 25:125-142.